Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant

• Status: Completed
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aims of this study are to prospectively evaluate the efficacy of two intravenous infusions of pamidronate 90 mg, associated with calcium and calcidiol, in the early post-transplant period, on bone loss in liver transplant recipients, and to asses the safety of this treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Collaborator: Novartis
• Treatments: Diphosphonates; Liver Extracts; Pamidronate

Criteria

Inclusion Criteria:

• diagnosed with chronic advanced liver disease awaiting orthotopic liver transplantation

Exclusion Criteria:

• younger than 18 years

• receiving a multiorgan transplant or retransplant

• previous allergy to bisphosphonates

• Previous treatment with fluoride, estrogens, selective estrogen receptor modulators or bisphosphonates

• therapy with glucocorticoids during the last 6 months before transplantation

• previous history of disorders, other than liver disease, known to affect bone metabolism.